Next Article in Journal
Beyond Trisomy 21: Additional Chromosomal Anomalies Detected through Routine Aneuploidy Screening
Previous Article in Journal
Hyponatremia: A Risk Factor for Early Overt Encephalopathy after Transjugular Intrahepatic Portosystemic Shunt Creation
Previous Article in Special Issue
Towards a Treatment of Stress Urinary Incontinence: Application of Mesenchymal Stromal Cells for Regeneration of the Sphincter Muscle
Open AccessReview

The Power and the Promise of Cell Reprogramming: Personalized Autologous Body Organ and Cell Transplantation

Control of Pluripotency Laboratory, Department of Physiological Sciences I, Faculty of Medicine, University of Barcelona, Hospital Clinic, Casanova 143, Barcelona 08036, Spain
School of Medicine and Pharmacology, University of Western Australia, Crawley, Perth, WA 6009, Australia
Pathwest, Nedlands, WA 6009, Australia
Ear Sciences Centre, School of Surgery, University of Western Australia, Nedlands, WA 6009, Australia
Centre for Ophthalmology and Visual Science (Lions Eye Institute), University of Western Australia, Perth, WA 6009, Australia
Institute for Immunology and Infectious Diseases, Murdoch University, Murdoch, Perth, WA 6150, Australia
Immunology Unit, Department of Cell Biology, Physiology and Immunology and Institute of Biotechnology and Biomedicine, Universitat Autònoma de Barcelona, Bellaterra 08193, Spain
Senior Research Fellow at the University of Sydney Medical School, Faculty of Medicine, Westmead Children's Hospital, Division of Pediatrics and Child Health, Sydney, NSW 2145, Australia
Author to whom correspondence should be addressed.
J. Clin. Med. 2014, 3(2), 373-387;
Received: 14 January 2014 / Revised: 17 February 2014 / Accepted: 19 February 2014 / Published: 4 April 2014
(This article belongs to the Special Issue Frontiers in Stem Cell Treatments)
Reprogramming somatic cells to induced pluripotent stem cells (iPSCs) or direct reprogramming to desired cell types are powerful and new in vitro methods for the study of human disease, cell replacement therapy, and drug development. Both methods to reprogram cells are unconstrained by the ethical and social questions raised by embryonic stem cells. iPSC technology promises to enable personalized autologous cell therapy and has the potential to revolutionize cell replacement therapy and regenerative medicine. Potential applications of iPSC technology are rapidly increasing in ambition from discrete cell replacement applications to the iPSC assisted bioengineering of body organs for personalized autologous body organ transplant. Recent work has demonstrated that the generation of organs from iPSCs is a future possibility. The development of embryonic-like organ structures bioengineered from iPSCs has been achieved, such as an early brain structure (cerebral organoids), bone, optic vesicle-like structures (eye), cardiac muscle tissue (heart), primitive pancreas islet cells, a tooth-like structure (teeth), and functional liver buds (liver). Thus, iPSC technology offers, in the future, the powerful and unique possibility to make body organs for transplantation removing the need for organ donation and immune suppressing drugs. Whilst it is clear that iPSCs are rapidly becoming the lead cell type for research into cell replacement therapy and body organ transplantation strategies in humans, it is not known whether (1) such transplants will stimulate host immune responses; and (2) whether this technology will be capable of the bioengineering of a complete and fully functional human organ. This review will not focus on reprogramming to iPSCs, of which a plethora of reviews can be found, but instead focus on the latest developments in direct reprogramming of cells, the bioengineering of body organs from iPSCs, and an analysis of the immune response induced by iPSC-derived cells and tissues. View Full-Text
Keywords: direct cell reprogramming; iPSC; autologous; immune response; organ bioengineering direct cell reprogramming; iPSC; autologous; immune response; organ bioengineering
MDPI and ACS Style

Palomo, A.B.A.; Lucas, M.; Dilley, R.J.; McLenachan, S.; Chen, F.K.; Requena, J.; Sal, M.F.; Lucas, A.; Alvarez, I.; Jaraquemada, D.; Edel, M.J. The Power and the Promise of Cell Reprogramming: Personalized Autologous Body Organ and Cell Transplantation. J. Clin. Med. 2014, 3, 373-387.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

Only visits after 24 November 2015 are recorded.
Back to TopTop